Jacobs Levy Equity Management’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-767,135
| Closed | -$7.21M | – | 1142 |
|
|
2020
Q3 | $7.21M | Sell |
767,135
-28,476
| -4% | -$271K | 0.07% | 270 |
|
|
2020
Q2 | $6.09M | Sell |
795,611
-679
| -0.1% | -$5.2K | 0.07% | 300 |
|
|
2020
Q1 | $4.92M | Buy |
796,290
+68,903
| +9% | +$607K | 0.06% | 296 |
|
|
2019
Q4 | $8.85M | Buy |
727,387
+213,067
| +41% | +$2.33M | 0.09% | 268 |
|
|
2019
Q3 | $5.94M | Buy |
514,320
+66,605
| +15% | +$701K | 0.07% | 306 |
|
|
2019
Q2 | $4.47M | Buy |
447,715
+179,310
| +67% | +$1.93M | 0.06% | 369 |
|
|
2019
Q1 | $3.46M | Buy |
268,405
+206,972
| +337% | +$3.08M | 0.05% | 399 |
|
|
2018
Q4 | $933K | Buy |
61,433
+32,633
| +113% | +$622K | 0.02% | 608 |
|
|
2018
Q3 | $576K | Sell |
28,800
-85,360
| -75% | -$1.94M | 0.01% | 750 |
|
|
2018
Q2 | $2.23M | Buy |
114,160
+73,560
| +181% | +$1.63M | 0.04% | 485 |
|
|
2018
Q1 | $818K | Buy |
+40,600
| New | +$687K | 0.01% | 679 |
|
|
2015
Q1 | – | Sell |
-8,200
| Closed | -$349K | – | 919 |
|
|
2014
Q4 | $349K | Buy |
+8,200
| New | +$296K | 0.01% | 657 |
|
|
2014
Q2 | – | Sell |
-52,241
| Closed | -$1.01M | – | 969 |
|
|
2014
Q1 | $1.01M | Sell |
52,241
-20,800
| -28% | -$442K | 0.02% | 535 |
|
|
2013
Q4 | $1.77M | Buy |
73,041
+45,281
| +163% | +$1.06M | 0.03% | 452 |
|
|
2013
Q3 | $596K | Sell |
27,760
-11,000
| -28% | -$260K | 0.01% | 647 |
|
|
2013
Q2 | $862K | Buy |
+38,760
| New | +$854K | 0.02% | 604 |
|
Jacobs Levy Equity Management's AMAG Position: Q4 2020 in Review
Jacobs Levy Equity Management sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 767,135 shares — an estimated $7.21M sold.
Jacobs Levy Equity Management first reported a position in AMAG in Q2 2013 and held it in 16 quarters. The position peaked at $8.85M in Q4 2019. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Jacobs Levy Equity Management reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Jacobs Levy Equity Management sold 767,135 AMAG Pharmaceuticals shares in Q4 2020, an estimated $7.21M.
- Jacobs Levy Equity Management first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 16 quarters.
- Jacobs Levy Equity Management's AMAG Pharmaceuticals position peaked at $8.85M in Q4 2019.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Jacobs Levy Equity Management's 13F filing for Q4 2020, filed 16 Feb 2021.